# Retapamulin for Reducing MRSA Nasal Carriage

> **NCT01461668** · PHASE4 · COMPLETED · sponsor: **University of California, Irvine** · enrollment: 53 (actual)

## Conditions studied

- Methicillin-Resistant Staphylococcus Aureus

## Interventions

- **DRUG:** Retapamulin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01461668
- **Lead sponsor:** University of California, Irvine
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-07
- **Primary completion:** 2017-12
- **Final completion:** 2017-12
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2018-04-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01461668

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01461668, "Retapamulin for Reducing MRSA Nasal Carriage". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01461668. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*